Analysts Expect Coherus Biosciences Inc (CHRS) Will Post Earnings of -$0.90 Per Share

Brokerages forecast that Coherus Biosciences Inc (NASDAQ:CHRS) will report earnings per share (EPS) of ($0.90) for the current quarter, Zacks reports. Zero analysts have issued estimates for Coherus Biosciences’ earnings. Coherus Biosciences posted earnings per share of ($1.71) in the same quarter last year, which indicates a positive year over year growth rate of 47.4%. The company is expected to issue its next quarterly earnings results on Monday, March 12th.

According to Zacks, analysts expect that Coherus Biosciences will report full year earnings of ($4.39) per share for the current financial year, with EPS estimates ranging from ($4.55) to ($4.23). For the next fiscal year, analysts forecast that the company will post earnings of ($2.91) per share, with EPS estimates ranging from ($3.10) to ($2.71). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Coherus Biosciences.

A number of research analysts have issued reports on the company. Zacks Investment Research cut Coherus Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. Citigroup reaffirmed a “buy” rating and set a $23.00 price objective on shares of Coherus Biosciences in a research report on Tuesday, November 7th. ValuEngine raised Coherus Biosciences from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. Finally, BidaskClub raised Coherus Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. Two analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. Coherus Biosciences currently has an average rating of “Buy” and an average price target of $29.67.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Temasek Holdings Private Ltd bought a new stake in Coherus Biosciences during the third quarter worth about $87,524,000. Vanguard Group Inc. raised its holdings in Coherus Biosciences by 2.1% during the second quarter. Vanguard Group Inc. now owns 2,255,467 shares of the biotechnology company’s stock worth $32,367,000 after acquiring an additional 46,223 shares in the last quarter. Citadel Advisors LLC raised its holdings in Coherus Biosciences by 819.9% during the fourth quarter. Citadel Advisors LLC now owns 1,772,241 shares of the biotechnology company’s stock worth $15,595,000 after acquiring an additional 1,579,582 shares in the last quarter. State Street Corp raised its holdings in Coherus Biosciences by 26.8% during the second quarter. State Street Corp now owns 1,416,572 shares of the biotechnology company’s stock worth $20,329,000 after acquiring an additional 298,986 shares in the last quarter. Finally, UBS Asset Management Americas Inc. raised its holdings in Coherus Biosciences by 5.5% during the fourth quarter. UBS Asset Management Americas Inc. now owns 1,393,661 shares of the biotechnology company’s stock worth $12,264,000 after acquiring an additional 72,710 shares in the last quarter. Institutional investors and hedge funds own 78.80% of the company’s stock.

Shares of Coherus Biosciences (NASDAQ CHRS) opened at $9.45 on Monday. The company has a debt-to-equity ratio of 1.84, a quick ratio of 5.46 and a current ratio of 5.46. Coherus Biosciences has a 52 week low of $8.05 and a 52 week high of $26.55. The company has a market capitalization of $565.49, a price-to-earnings ratio of -1.74 and a beta of 3.81.

TRADEMARK VIOLATION WARNING: This report was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2018/02/12/analysts-expect-coherus-biosciences-inc-chrs-will-post-earnings-of-0-90-per-share.html.

About Coherus Biosciences

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Get a free copy of the Zacks research report on Coherus Biosciences (CHRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply